Answers are grounded in this paper and cite their sources.
Bladder cancer requires additional therapeutic strategies because of frequent recurrence and progression risk. We evaluated recombinant Mycobacterium smegmatis expressing a human macrophage migration inhibitory factor–interleukin-7 fusion protein (rSmeg-hMIF-hIL-7) in a syngeneic subcutaneous MBT-2 bladder cancer model. Among mice that developed measurable tumors, intraperitoneally treated mice showed reduced tumor growth and longer endpoint-free survival, defined as time to death or humane-endpoint euthanasia. RNA sequencing of four control and three treated tumors identified 116 differentially expressed genes at a fold-change magnitude ≥ 2 and false discovery rate (FDR) < 0.05. Enrichment analyses highlighted immune-related transcriptional differences, although tissue-collection timing and tumor burden limited their attribution to treatment. Cross-species expression comparison identified five exploratory candidates: CCL15, CCRL2, ST3GAL5, SIGLEC6, and TMEM255A. Four showed FDR-significant survival associations in exploratory unadjusted Cox analyses within the same TCGA-BLCA cohort. Expression patterns concordant with those in treated mouse tumors were also associated with papillary histology. RT-qPCR using the same biological samples supported increased Ccl6 and St3gal5 expression after multiple-testing correction. These findings support the antitumor potential of rSmeg-hMIF-hIL-7 and provide exploratory links between murine tumor transcriptional differences and human bladder cancer characteristics.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: